We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Truist has recently reduced Merck & Co Inc (MRK) stock to Hold rating, as announced on January 8, 2025, according to Finviz. Earlier, on December 20, 2024, BMO Capital Markets had reduced the stock ...

Merck shares are down more than 20% over the past 12 months after trouble with sales of its Gardasil vaccine in China ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck & Co. Inc. closed 27.25% short of its 52-week high of $134.63, which the company reached on June 25th.

Shares of this pharmaceutical company have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1.2% change. The Zacks Large Cap Pharmaceuticals industry, to which Merck ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

The healthcare pioneer shares insights on transformative diagnostics where precision medicine meets women’s health innovation ...